231 related articles for article (PubMed ID: 24997557)
21. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
22. Velcade, Doxil and Thalidomide (VDT) is an effective salvage regimen for patients with relapsed and refractory multiple myeloma.
Chanan-Khan A; Miller KC
Leuk Lymphoma; 2005 Jul; 46(7):1103-4. PubMed ID: 16019567
[No Abstract] [Full Text] [Related]
23. Autologous retransplantation for patients with recurrent multiple myeloma: a single-center experience with 200 patients.
Sellner L; Heiss C; Benner A; Raab MS; Hillengass J; Hose D; Lehners N; Egerer G; Ho AD; Goldschmidt H; Neben K
Cancer; 2013 Jul; 119(13):2438-46. PubMed ID: 23576287
[TBL] [Abstract][Full Text] [Related]
24. Upregulated expression of the PSMB5 gene may contribute to drug resistance in patient with multiple myeloma when treated with bortezomib-based regimen.
Shuqing L; Jianmin Y; Chongmei H; Hui C; Wang J
Exp Hematol; 2011 Dec; 39(12):1117-8. PubMed ID: 21920470
[No Abstract] [Full Text] [Related]
25. Phase I trial of first-line bortezomib/thalidomide plus chemotherapy for induction and stem cell mobilization in patients with multiple myeloma.
Badros A; Goloubeva O; Fenton R; Rapoport AP; Akpek G; Harris C; Ruehle K; Westphal S; Meisenberg B
Clin Lymphoma Myeloma; 2006 Nov; 7(3):210-6. PubMed ID: 17229337
[TBL] [Abstract][Full Text] [Related]
26. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
27. [Outcome of bortezomib plus chemotherapy with or without stem cell transplantation for treatment of multiple myeloma].
Wang YF; Deng SH; Wu T; Xu Y; Zou DH; Wang Y; Zhao YZ; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2008 Jun; 29(6):397-400. PubMed ID: 19031743
[TBL] [Abstract][Full Text] [Related]
28. Novel approaches to the management of myeloma.
Rajkumar SV
Oncology (Williston Park); 2005 Apr; 19(5):621-5. PubMed ID: 15948290
[TBL] [Abstract][Full Text] [Related]
29. [Treatment of transplant-eligible symptomatic multiple myeloma].
Nakaseko C
Rinsho Ketsueki; 2014 Oct; 55(10):2016-26. PubMed ID: 25297767
[No Abstract] [Full Text] [Related]
30. Assessment of molecular remission rate after bortezomib plus dexamethasone induction treatment and autologous stem cell transplantation in newly diagnosed multiple myeloma patients.
Silvennoinen R; Kairisto V; Pelliniemi TT; Putkonen M; Anttila P; Säily M; Sikiö A; Opas J; Penttilä K; Kuittinen T; Honkanen T; Lundán T; Juvonen V; Luukkaala T; Remes K
Br J Haematol; 2013 Feb; 160(4):561-4. PubMed ID: 23206270
[No Abstract] [Full Text] [Related]
31. Rapid control of previously untreated multiple myeloma with bortezomib-lenalidomide-dexamethasone (BLD).
Wang M; Delasalle K; Giralt S; Alexanian R
Hematology; 2010 Apr; 15(2):70-3. PubMed ID: 20423566
[TBL] [Abstract][Full Text] [Related]
32. Side effects and good effects from new chemotherapeutic agents. Case 3. Bortezomib in primary refractory plasmacytoma.
Chim CS; Ooi GC; Loong F; Au AW; Lie AK
J Clin Oncol; 2005 Apr; 23(10):2426-8. PubMed ID: 15800336
[No Abstract] [Full Text] [Related]
33. Hepatic extramedullary disease in multiple myeloma with 17p deletion.
Ise M; Tsujimura H; Sakai C; Kumagai K
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):e165-8. PubMed ID: 25018063
[No Abstract] [Full Text] [Related]
34. Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib.
Idbaih A; Mokhtari K; Emile JF; Galanaud D; Belaid H; de Bernard S; Benameur N; Barlog VC; Psimaras D; Donadieu J; Carpentier C; Martin-Duverneuil N; Haroche J; Feuvret L; Zahr N; Delattre JY; Hoang-Xuan K
Neurology; 2014 Oct; 83(16):1478-80. PubMed ID: 25209580
[No Abstract] [Full Text] [Related]
35. Targeting BRAF in multiple myeloma.
O'Donnell E; Raje NS
Cancer Discov; 2013 Aug; 3(8):840-2. PubMed ID: 23928771
[TBL] [Abstract][Full Text] [Related]
36. Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Ozaki S; Harada T; Saitoh T; Shimazaki C; Itagaki M; Asaoku H; Kuroda Y; Chou T; Yoshiki Y; Suzuki K; Murakami H; Hayashi K; Mina R; Palumbo A; Shimizu K; ;
Acta Haematol; 2014; 132(2):211-9. PubMed ID: 24662986
[TBL] [Abstract][Full Text] [Related]
37. Complete remission following treatment with bortezomib, doxorubicin, dexamethasone and autologous stem cell transplant in patient with immunoglobulin E multiple myeloma.
Pogłód R; Kraj M; Kruk B; Hagedorna-Tronina R; Łetowska M; Warzocha K
Leuk Lymphoma; 2010 Dec; 51(12):2291-4. PubMed ID: 20929320
[No Abstract] [Full Text] [Related]
38. Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.
Kuroda J; Kobayashi T; Tsutsumi Y; Yamamoto M; Ohshiro M; Sasaki N; Shimura Y; Mizutani S; Nagoshi H; Kiyota M; Nakayama R; Uchiyama H; Matsumoto Y; Horiike S; Shimazaki C; Taniwaki M
Int J Hematol; 2010 Nov; 92(4):669-72. PubMed ID: 20978877
[No Abstract] [Full Text] [Related]
39. [New treatment strategies for multiple myeloma].
Ozaki S
Rinsho Ketsueki; 2009 Oct; 50(10):1506-17. PubMed ID: 19915360
[No Abstract] [Full Text] [Related]
40. Successful vemurafenib salvage treatment in a patient with primary refractory hairy cell leukemia and pulmonary aspergillosis.
Maurer H; Haas P; Wengenmayer T; Lübbert M; Duyster J; Zeiser R
Ann Hematol; 2014 Aug; 93(8):1439-40. PubMed ID: 24337488
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
